Explore

Trendline Trendline
Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors

Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors

Innate Pharma Completes Enrollment in Phase 1 Study of IPH4502, Targeting Advanced Solid Tumors
Trendline Trendline
Incyte to Present Data on Cancer Treatments at ESMO Congress 2026

Incyte to Present Data on Cancer Treatments at ESMO Congress 2026

Incyte to Present Data on Cancer Treatments at ESMO Congress 2026
Trendline Trendline
Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder
Trendline Trendline
Xencor to Present Phase 1 Study Results of XmAb819 in Renal Cell Carcinoma at ESMO 2026

Xencor to Present Phase 1 Study Results of XmAb819 in Renal Cell Carcinoma at ESMO 2026

Xencor to Present Phase 1 Study Results of XmAb819 in Renal Cell Carcinoma at ESMO 2026
Trendline Trendline
Agenus to Present Immunotherapy Advances at ESMO 2026, Highlighting Colorectal Cancer and Sarcoma Studies

Agenus to Present Immunotherapy Advances at ESMO 2026, Highlighting Colorectal Cancer and Sarcoma Studies

Agenus to Present Immunotherapy Advances at ESMO 2026, Highlighting Colorectal Cancer and Sarcoma Studies
SB Nation SB Nation
Raúl Asencio’s trainer explains Real Madrid defender’s mentality ahead of new season: “He has all the qualities to succeed”

Raúl Asencio’s trainer explains Real Madrid defender’s mentality ahead of new season: “He has all the qualities to succeed”

Luiso Hernández says the defender believes his personality makes him built for Real Madrid
Trendline Trendline
Xencor to Present Phase 1 Study Results of XmAb819 for Advanced Renal Cell Carcinoma at ESMO 2026

Xencor to Present Phase 1 Study Results of XmAb819 for Advanced Renal Cell Carcinoma at ESMO 2026

Xencor to Present Phase 1 Study Results of XmAb819 for Advanced Renal Cell Carcinoma at ESMO 2026
Trendline Trendline
Xencor's XmAb819 Phase 1 Study Results to be Presented at ESMO 2026, Highlighting Potential in Renal Cell Carcinoma

Xencor's XmAb819 Phase 1 Study Results to be Presented at ESMO 2026, Highlighting Potential in Renal Cell Carcinoma

Xencor's XmAb819 Phase 1 Study Results to be Presented at ESMO 2026, Highlighting Potential in Renal Cell Carcinoma
Trendline Trendline
Agenus to Present BOT+BAL Cancer Research at ESMO 2026, Highlighting Advances in Colorectal and Sarcoma Treatments

Agenus to Present BOT+BAL Cancer Research at ESMO 2026, Highlighting Advances in Colorectal and Sarcoma Treatments

Agenus to Present BOT+BAL Cancer Research at ESMO 2026, Highlighting Advances in Colorectal and Sarcoma Treatments